Figure 2.

Composite responders over weeks 1–4 who remained responders over weeks 1–12, weeks 1–26, weeks 9–12 and weeks 21–24: pooled analysis of Phase 3 studies. ^aData shown in Lembo et al.14 Composite response is based on daily improvement of ≥30% in worst abdominal pain score compared with average baseline pain and, on the same day, a Bristol Stool Form Scale score of <5, on ≥50% of treatment days.